Combining Gemcitabine With Radiation in Pancreatic Cancer: Understanding Important Variables Influencing the Therapeutic Index
References (34)
- et al.
Maximizing therapeutic gain with gemcitabine and fractionated radiation
Int J Radiat Oncol Biol Phys
(1999) - et al.
Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine
Int J Radiat Oncol Biol Phys
(1996) - et al.
Radiosensitization produced in vivo by once- vs
twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine). Int J Radiat Oncolo Biol Phys
(2000) - et al.
Treatment related tuxicities with rapid-fractionation external beam radiation and concomitant gemcitabine for locally advanced nonmetastatic adenocarcinoma of the pancreas
Int J Radiat Oncol Biol Phys
(1998) - et al.
Phase II study of gemcitabine (GEM) combined with radiation therapy (RT) in localized, unresectable pancreatic cancer
Eur J Cancer
(1999) Gemcitabine: A pharmacologic and clinical overview
Cancer Nuts
(1999)- et al.
Enhancement of tumor radioresponse in vivo by gemcitabine
Cancer Res
(1999) - et al.
Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model
Radiat Oncol Invest
(1997) - et al.
Gemeitabmemediated radiosensittzation
Semin Oncol
(1997) - et al.
Radiosensitizing nucleosides
J Natl Cancer Inst
(1996)
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
Invest New Drugs
(1994)
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
J Clin Oncol
(1991)
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
J Clin Oncot
(1997)
Gemcitabine: Effective palliative therapy for pancreas cancer patients failing 5-FU
Proc Am Soc Clin Oncol
(1995)
Gemcitabine radiosensitizes human pancreas cancer cells
Proc Am Assoc Cancer Res
(1994)
Pancreatic cancer: Value of dual-phase helical CT in assessing resectability
Radiology
(1998)
Pancreatic ductal adenocarcinoma: Preoperative assessment with helical CT versus dynamic MR imaging
Radiology
(1997)
Cited by (0)
This work was supported in part by the National Cancer Institute, Department of Health and Human Services, grant no. CA06294 and CA16672, and grants from the Radiological Society of North America, the Physicians Referral Service Children's Art Project at M. D. Anderson Cancer Center, and Eli Lilly Research Laboratories, Indianapolis, IN.
- b
Drs Wolff and Abbruzzese serve on the speakers bureau for Eli Lilly and Company.
Copyright © 2001 W. B. Saunders Company. Published by Elsevier Inc. All rights reserved.